home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

31.88 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? ↗

July 20, 2025

Via The Motley Fool

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗

July 19, 2025

Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

Via The Motley Fool

Topics Intellectual Property

The Best Stocks to Invest $1,000 In Right Now ↗

July 15, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy

Better Growth Buy: Eli Lilly vs. Viking Therapeutics ↗

July 07, 2025

Via The Motley Fool

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity ↗

July 04, 2025

Via The Motley Fool

Topics Artificial Intelligence

2 Beaten-Down Stocks With Massive Upside Potential ↗

July 03, 2025

Via The Motley Fool

10 Incredible Growth Stocks Poised for Long-Term Gains ↗

July 02, 2025

Via The Motley Fool

Topics Artificial Intelligence

Got $200? 2 Biotech Stocks to Buy and Hold Forever ↗

July 01, 2025

Via The Motley Fool

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

June 29, 2025

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

Via MarketBeat

Topics Artificial Intelligence Economy

Why This Weight Loss Drug Company's Stock Surged Today ↗

June 26, 2025

Via The Motley Fool

3 Growth Stocks I'm Loading Up On ↗

June 26, 2025

Via The Motley Fool

Topics Artificial Intelligence Government

Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity ↗

June 25, 2025

The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.

Via Investor's Business Daily

What's Going On With Viking Therapeutics Stock On Wednesday? ↗

June 25, 2025

Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.

Via Benzinga

My 5 Favorite Dirt Cheap Stocks to Buy Right Now ↗

June 24, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy World Trade

Amgen Expands Development Plans For Highly Anticipated Obesity Drug ↗

June 23, 2025

Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.

Via Investor's Business Daily

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts ↗

June 21, 2025

Via The Motley Fool

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. ↗

June 18, 2025

Via The Motley Fool

Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks? ↗

June 16, 2025

Via The Motley Fool

Topics Government

10 Health Care Stocks Whale Activity In Today's Session ↗

June 10, 2025

Via Benzinga

1 Stock Down 34% This Year to Buy and Hold ↗

June 08, 2025

Via The Motley Fool

Could Viking Therapeutics Become the Next Eli Lilly? ↗

June 02, 2025

Via The Motley Fool

3 Best Growth Stocks to Buy in June ↗

June 02, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Better Weight Loss Stock: Amgen or Viking Therapeutics? ↗

May 22, 2025

Via The Motley Fool

Why Viking Therapeutics Stock Bumped 3% Higher Today ↗

May 16, 2025

Via The Motley Fool

Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗

May 16, 2025

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Via Investor's Business Daily

Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗

May 13, 2025

Via The Motley Fool

Topics Government

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years ↗

May 13, 2025

Via The Motley Fool

3 Monster Stocks in the Making ↗

May 11, 2025

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 09, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com